Analysis of adverse drug reactions of Osimertinib in the 2nd-line treatment of EGFR mutant advanced nonsmall cell lung cancer-MedSci.cn

Analysis of adverse drug reactions of Osimertinib in the 2nd-line treatment of EGFR mutant advanced nonsmall cell lung cancer

Jiang, YY; Shi, Y; Wang, ZH; Li, H; Wang, ZT; He, K; Ma, YX; Xue, JJ; Shi, YM; Lu, JW; Shi, MQ; Shen, B; Zhou, GR; Wang, XH; Chen, C; Feng, JF

Wang, XH; Feng, JF (通讯作者)，Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Dept Oncol, Nanjing 21009, Jiangsu, Peoples R China.;Chen, C (通讯作者)，Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Dept Radiotherapy, Nanjing 21009, Jiangsu, Peoples R China.

Abstract

The aim was to analyze the clinical characteristics of adverse drug reactions (ADRs) induced by Osimertinib and their effects on the prognosis, so as ......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Analysis of adverse drug reactions of Osimertinib in the 2nd-line treatment of EGFR mutant advanced nonsmall cell lung cancer

科室

工具

服务